Skip to content
Clinical Trials – home
Therapeutic area

Infections and infestations – page 36

  • 677 clinical trials
  • 261 recruiting
  • 278 conditions
  • 27 countries

Conditions in this area

278 conditions with trials, the busiest first

Clinical trials in Infections and infestations

677 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

677 clinical trials

Chronic hepatitis B

Not recruiting

Study of GSK3965193 and Bepirovirsen for People Living with Chronic Hepatitis B Infection and Healthy Participants

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Herpes zoster

Not recruiting

A study of immune system response in adults who develop shingles after receiving recombinant herpes zoster vaccine to understand vaccine protection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:Centre hospitalier universitaire de Liege

COVID-19

Not recruiting

A Study Testing mRNA-1273 Vaccine Safety and Effectiveness Against Severe COVID-19 in Adults Aged 50-64 Years Without Risk Factors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · Healthy volunteers
  • Substances:Elasomeran
  • Sponsor:Gentofte Hospital

Influenza

Not recruiting

A Study to Test the Safety and Body's Response to TETRALITE Influenza Vaccine Compared to Vaxigrip Tetra Vaccine in Healthy Adults Aged 18 to 50 Years

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:A/Victoria/2570/2019 (H1N1)Pdm09-Like Strain (A/Victoria/2570/2019, Ivr-215)
  • Sponsor:LiteVax B.V.

COVID-19

Not recruiting

A study to test the safety and immune response of PHH-1V111 vaccine against COVID-19 variants in adults

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years · Healthy volunteers
  • Sponsor:Hipra Scientific S.L.

Influenza

Not recruiting

Study of mRNA-based seasonal influenza vaccine to evaluate immune response and safety in adults 18 years and older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:GSKVX000000034794
  • Sponsor:GlaxoSmithKline Biologicals

Avian influenza

Not recruiting

Study of H5N8 influenza vaccine in adults previously vaccinated with H5N1/MF59 vaccine compared to those never vaccinated with H5 vaccine

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:University Of Antwerp

Study of Rezafungin in Blood and Peritoneal Fluid for Patients with Suspected Intra-Abdominal Candidiasis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Rezafungin Acetate
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal

Comparing liquid versus capsule forms of phosphatidylcholine in patients with alcoholic liver disease, chronic hepatitis B, and metabolic liver disease

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Opella Healthcare Group S.A.S.

Pertussis

Not recruiting

Study of acellular pertussis vaccine and its effect on whooping cough colonization in healthy adults using controlled human infection

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Azithromycin
  • Sponsor:Stichting Radboud University Medical Center

Pneumonia viral

Not recruiting

Study of inhaled interferon beta-1a (SNG001) for treatment of patients with viral lower respiratory tract infections who require mechanical ventilation

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Interferon Beta-1A
  • Sponsor:Synairgen Research Limited

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
  • Sponsor:GlaxoSmithKline Biologicals

Substances studied in this area

The therapies tested most often in Infections and infestations trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.